Tapinarof - Celestial Pharmaceuticals/Stiefel Laboratories/Welichem Biotech

Drug Profile

Tapinarof - Celestial Pharmaceuticals/Stiefel Laboratories/Welichem Biotech

Alternative Names: Benvitimod; DHPS; GSK-2894512; WBI-1001

Latest Information Update: 24 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Welichem Biotech
  • Developer Beijing Wenfeng Tianji Pharmaceuticals; Celestial Pharmaceuticals; Stiefel Laboratories; Welichem Biotech
  • Class Antipsoriatics; Nonsteroidal anti-inflammatories; Resorcinols; Skin disorder therapies; Small molecules; Stilbenes
  • Mechanism of Action Aryl hydrocarbon receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Psoriasis
  • Phase II Atopic dermatitis; Plaque psoriasis
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 04 Sep 2018 Dermavant Sciences plans a phase III trial in 2019
  • 20 Aug 2018 Dermavant Sciences closes its transaction with GlaxoSmithKline for the purchase of all global rights to tapinarof, except in China
  • 12 Jul 2018 Dermavant Sciences signs agreement with GlaxoSmithKline to purchase global rights to tapinarof, except in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top